MindImmune Therapeutics agrees to acquire two programs from H. Lundbeck

MINDIMMUNE THERAPEUTICS has entered into an agreement with Lundbeck tow acquire two programs related to neuropathic pain and Huntington's disease. / COURTESY MINDIMMUNE THERAPEUTICS
MINDIMMUNE THERAPEUTICS has entered into an agreement with Lundbeck tow acquire two programs related to neuropathic pain and Huntington's disease. / COURTESY MINDIMMUNE THERAPEUTICS
SOUTH KINGSTOWN –MindImmune Therapeutics Inc. has entered into agreements with H. Lundbeck A/S to acquire programs and will develop candidates from these programs as novel therapeutics to treat neuropathic pain and Huntington’s disease, the company announced Wednesday. The programs target two neuroinflammation targets: P2X7 receptors and KMO, an enzyme in the neuroimmune kynurenine-signaling pathway, according…
Free Access WeekRegister to read all articles free until July 29! One week only, get full access to all articles on PBN.com when you create a complimentary account. Register Now Already a Subscriber or Registrant? Login now

No posts to display